Ignite Creation Date:
2024-05-05 @ 11:33 AM
Last Modification Date:
2024-10-26 @ 9:09 AM
Study NCT ID:
NCT00070629
Status:
COMPLETED
Last Update Posted:
2009-02-10
First Post:
2003-10-06
Brief Title:
CPG 7909 Injection in Non-Small Cell Lung Cancer
Sponsor:
Pfizer
Organization:
Pfizer
Study Overview
Official Title:
Promune CPG 7909 Injection In Combination With Chemotherapy In Patients With Advanced Or Metastatic Non-Small Cell Lung Cancer A Randomized Multi-Center Controlled Phase 2 Study
Status:
COMPLETED
Status Verified Date:
2009-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Eligible patients will be randomized in a ratio of 21 to receive either chemotherapy a taxane and a platinum compound plus CPG 7909 Injection or chemotherapy alone Protocol therapy will be administered until disease progression or intolerable toxicity CpG 7909 Injection will be administered subcutaneously on Weeks 2 and 3 of each three-week cycle days 8 and 15 and chemotherapy will be administered on Week 1 Day 1 Patients will undergo complete disease evaluation at the end of every other treatment cycle until disease progression
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| A8501017 | None | None | None |
| ProMune | None | None | None |
| CO17 | None | None | None |